Vectus Biosystems Wins FDA Pre-IND Meeting Step for Lung Disease Drug
VBS: $0.079 +0.00% · MC: $4M
The FDA granted Vectus Biosystems’ request for a pre-IND Type B meeting on VB0004 for idiopathic pulmonary fibrosis, with written feedback expected by mid-November to guide the next clinical and regulatory steps. The company appointed Cardinal Health Regulatory Services to support FDA communications and submissions. Cash on hand fell from approximately $719,000 to $410,000 during the quarter; a research and development tax refund of $208,000 was received in October.

Comments